Alpha-ketoglutarate is the most underrated longevity molecule and nobody's funding human trials
In 2020, Asadi Shahmirzadi et al. published in Cell Metabolism showing alpha-ketoglutarate (AKG) extended mouse lifespan 12% and compressed morbidity 40%. Extraordinary healthspan data—reduced frailty, preserved fur, improved grip strength. Three years later: essentially zero human longevity trials.
Why AKG matters: It sits at the nexus of multiple aging pathways. TCA cycle intermediate, cofactor for DNA/histone demethylases (TET enzymes, JmjC proteins), ATP synthase inhibitor mimicking energetic stress. It hits mTOR, epigenetic regulation, and mitochondrial function simultaneously.
The epigenetic angle is compelling. AKG is required for TET enzyme function—enzymes that demethylate DNA. As AKG declines with age, TET activity drops, aberrant DNA methylation accumulates. This likely drives epigenetic clock acceleration.
What makes AKG uniquely promising:
- GRAS status—already sold as supplement
- Cheap (<$20/month at effective doses)
- Works in both sexes
- Rejuvenation effects visible within weeks
- The Rejuvant study showed 8-year epigenetic age reversal with AKG + vitamins
Testable prediction: AKG (1g/day calcium-AKG) for 6 months in adults 50-70 will show >4yr GrimAge reduction, improved T-cell diversity, >30% reduced inflammatory markers.
This trial costs $1-2M for 200 participants. Rejuvant data de-risks it. Why isn't a BioDAO running this now?
AKG might be the metformin alternative with better data and fewer side effects. Who's in?